Edesa Biotech, Inc. EDSA
Edesa Biotech, Inc. (Nasdaq: EDSA) is a respiratory drug developer. Its lead program, EB05 (paridiprubart), is in Phase 3 for Acute Respiratory Distress Syndrome (ARDS). Its next catalyst on record is EB06: Start of Phase 2 proof-of-concept enrollment in vitiligo (Health Canada approved; FDA IND CMC information being provided) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EB06 — Start of Phase 2 proof-of-concept enrollment in vitiligo (Health Canada approved; FDA IND CMC information being provided) (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EB05 (paridiprubart) | ARDS (truncated Phase 3 reported Oct 2025; ongoing US government-funded platform study) | antibody | Phase 3 |
| EB01 (daniluromer 1.0% cream) | chronic Allergic Contact Dermatitis (Phase 3-ready, at partnering stage) | small molecule | Phase 2 |
| EB06 | moderate-to-severe nonsegmental vitiligo | antibody | Phase 1 |
Recent results and decisions
- Feb 24, 2026met Additional Phase 3 data in the full 278-patient population: adjusted 28-day mortality 24% vs 33% on placebo (27% relative reduction, p<0.001).
Paridiprubart reduced adjusted 28-day mortality to 24% from 33%, a 27% relative reduction in the risk of death (p<0.001).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.